Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study ; volume:9 ; number:1 ; day:18 ; month:9 ; year:2009 ; pages:1-11 ; date:12.2009
BMC cancer ; 9, Heft 1 (18.9.2009), 1-11, 12.2009
- Urheber
-
Emery, Ivette F.
- Beteiligte Personen und Organisationen
-
Battelli, Chiara
Auclair, Paul L.
Carrier, Kathleen
Hayes, Daniel M.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-9-333
- URN
-
urn:nbn:de:1111-2016030351134
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Emery, Ivette F.
- Battelli, Chiara
- Auclair, Paul L.
- Carrier, Kathleen
- Hayes, Daniel M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Treatment with gefitinib after erlotinib-induced liver injury: a case report
Entwicklung einer medikamentenfreisetzenden Intraokularlinse mit den EGFR-Inhibitoren Erlotinib und Gefitinib
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Treatment with gefitinib after erlotinib-induced liver injury: a case report
Entwicklung einer medikamentenfreisetzenden Intraokularlinse mit den EGFR-Inhibitoren Erlotinib und Gefitinib
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Treatment with gefitinib after erlotinib-induced liver injury: a case report
Entwicklung einer medikamentenfreisetzenden Intraokularlinse mit den EGFR-Inhibitoren Erlotinib und Gefitinib
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship